Literature DB >> 12118546

C-Ki-ras mutations in peripheral blood of pancreatic cancer patients: a marker for early tumor metastasis.

M Mohiuddin1, M M Ahmed, K Venkatasubbarao.   

Abstract

PURPOSE: To determine the incidence of circulating minimal malignant clone (CMMC) (harboring c-Ki-ras-2 mutation) in peripheral blood (PB) samples of untreated pancreatic cancer using polymerase chain reaction (PCR) analysis of c-Ki-ras-2 oncogene. METHODS AND MATERIALS: Experiments were carried out in fresh tumor, peritoneal washings (PW), and PB samples of untreated pancreatic adenocarcinoma patients (both resectable and unresectable). Samples were taken from 16 patients diagnosed with pancreatic adenocarcinoma for the PCR analysis of mutated c-Ki-ras oncogene. Five tumor samples, 15 PB samples, and 3 PW samples were analyzed for point mutation of the c-Ki-ras gene at codon 12.
RESULTS: Out of five tumor samples analyzed for c-Ki-ras mutation, four were positive at the 12th codon. Out of total 15 PB samples, nine were positive for the c-Ki-ras point mutation at the 12th codon. All the positive PB samples showed a base substitution from GGT to GAT in the second position of the 12th codon. Out of three PW samples, two showed mutation at the second position from GGT to GAT similar to their PB and tumor samples.
CONCLUSION: Our study indicated the presence of the tumor cells (CMMC) in PB of pancreatic adenocarcinoma that can be identified by PCR analysis of c-Ki-ras oncogene. Patients with presence of CMMC in PB and mutation in PW had aggressive tumors that responded poorly to treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 12118546     DOI: 10.1016/0360-3016(95)02004-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Current and emerging treatments for pancreatic cancer.

Authors:  W F Regine; W J John; M Mohiuddin
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Efficacy of p120 antisense-mediated therapy for pancreatic cancer.

Authors:  J W Freeman; W E Strodel; P C McGrath
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 3.  Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Mansoor M Ahmed; C Norman Coleman
Journal:  Cancer Lett       Date:  2016-01-29       Impact factor: 8.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.